PLA2G1B

Across TCGA pan-cancer cohorts, PLA2G1B mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PLA2G1B data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PLA2G1B mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PLA2G1B expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD and LSCC are the cancer types where PLA2G1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.916	0.636	.013	3	view →
LSCC	DFS	Quartile	All	0.941	1.000	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

PLA2G1B–LUAD (OS)

Open the LUAD breakdown →